1321.7 Hemorrhage

Bleeding and Clotting Disorders


Condition or Disease: Hemorrhage

Study Type: Interventional (Clinical Trial)

Status: Open for enrollment

Study Title: Single dose, open label, uncontrolled, safety trial of intravenous administration of idarucizumab to paediatric patients enrolled from ongoing phase IIb/III clinical trials with dabigatran etexilate for the treatment and secondary prevention of venous thromboembolism.

Principal I investigator: Alan Ikeda, MD

More Info: //clinicaltrials.gov/ct2/show/NCT02815670

Share This Post

Explore More News


Rare Disease Advisory Council seeks input for healthier Nevada

The Rare Disease Advisory Council is seeking input from the public to help improve the health of Nevada residents. The council is focused on addressing the needs of those with rare diseases and is looking for feedback from patients, caregivers, and healthcare providers. The goal is to gather information that can be used to develop strategies and policies to improve the lives of those affected by rare diseases in Nevada.


Cure 4 The Kids Foundation Announces Senior Leadership Changes

Cure 4 The Kids Foundation is pleased to announce the appointment of Christine Tonn as its new chief executive officer (CEO), effective January 1, 2024. This promotion is part of a board of directors-supported management succession plan.